CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cann Global Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cann Global Ltd
Level 21, 133 Castlereagh Street
Phone: +61 292919000p:+61 292919000 SYDNEY, NSW  2000  Australia Fax: +61 292919099f:+61 292919099

This company is no longer actively traded on any major stock exchange.

Business Summary
Cann Global Limited is a health and wellness company. The principal activities of the Company and its subsidiaries are developing, growing, cultivating and producing hemp and medicinal cannabis products, and natural food products in the health and wellness industry. Its segments include hemp and medical cannabis products, mining exploration and evaluation and corporate. Its portfolio includes Cosmeceutical, Health Foods, and Cannabinoid Medicine. The Cosmeceutical range includes the brand Fuss Pot, which is a hemp-powered skincare brand. Its Grass Roots brand delivers a range of nutritious health-focused products that anyone can add to everyday meals and snacks. Its Grass Roots range includes nutritionist-endorsed solutions for everyday life. Its Instacann brand combines natural cannabis extracts with pharmaceutical formulations. Instacann’s tablets offer an alternative to other medicinal cannabis formats, through the use of a self-micro emulsifying drug delivery system (SMEDDS).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20226/30/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board DavidAustin 8/30/2021 8/30/2021
Chief Executive Officer, Managing Director, Executive Director SholomFeldman 1/1/2022
Chief Operating Officer MarionLesaffre 8/28/2020
Company Secretary AlexanderNeuling 8/21/2019 8/21/2019
Non-Executive Independent Director JonathanCohen 7/2/2019 7/2/2019

Business Names
Business Name
Australian Gold Investments Limited
Medcan Australia
Medical Cannabis Limited

General Information
Outstanding Shares: 258,873,557 (As of 6/30/2022)
Shareholders: 11,062
Stock Exchange: ASX
Fax Number: +61 292919099


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 13, 2024